Modality
Degrader
MOA
Anti-Aβ
Target
EZH2
Pathway
NF-κB
FL
Development Pipeline
Preclinical
~Jun 2024
→ ~Sep 2025
Phase 1
Dec 2025
→ Nov 2027
Phase 1Current
NCT04475998
2,292 pts·FL
2025-12→2027-11·Active
2,292 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2027-11-051.6y awayInterim· FL
Trial Timeline
2026Q2Q3Q42027Q2Q3Q4
P1
Active
Catalysts
Interim
2027-11-05 · 1.6y away
FL
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04475998 | Phase 1 | FL | Active | 2292 | EASI-75 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-8369 | Eli Lilly | Approved | Menin | |
| ABB-8696 | AbbVie | Phase 3 | BCMA | |
| BAY-6035 | Bayer | Phase 1 | C5 | |
| DSN-2247 | Daiichi Sankyo | NDA/BLA | EZH2 | |
| Zenotinib | BioNTech | Phase 1 | CGRP | |
| HAL-9635 | Halozyme | Phase 2/3 | EZH2 | |
| RLA-6817 | Relay Therapeutics | Phase 3 | TIGIT | |
| Lisoosocimab | Zealand Pharma | Approved | KIF18A | |
| PRA-419 | Praxis Precision | Approved | Cl18.2 | |
| TNG-8610 | Tango Ther | NDA/BLA | GIP-R |